Silo Pharma Inc. (NASDAQ: SILO) announced that its board of directors has authorized a share repurchase program to acquire up to $1 million of the company's common stock. The program allows purchases to be made on the open market, through privately negotiated transactions, or otherwise, in compliance with Securities and Exchange Commission rules and applicable legal requirements. As of November 13, 2025, the company reported 13,318,273 shares of common stock outstanding, according to its quarterly report for the period ended September 30, 2025.
The timing and amount of any repurchases will depend on market conditions and corporate and regulatory limitations. The program does not obligate the company to acquire a specific number of shares and may be suspended or discontinued at its discretion. This move indicates management's belief that the company's stock is undervalued and represents a strategic use of capital to enhance shareholder value.
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The company's portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. Silo's research is conducted in collaboration with leading universities and laboratories.
Share repurchase programs can be a signal of confidence from management, potentially supporting the stock price and improving earnings per share by reducing the number of shares outstanding. For investors, this announcement may be viewed positively as it demonstrates a commitment to returning value to shareholders. However, the actual impact will depend on the execution of the program and overall market conditions.
For more details, the full press release can be accessed at https://ibn.fm/gU3uZ. Additional news and updates relating to SILO are available in the company's newsroom at https://ibn.fm/SILO.
